HAMI 3379 is a potent and selectiveCysLT₂receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation^[1][2].

In a CysLT₂receptor reporter cell line, HAMI3379 antagonizes leukotriene D₄- (LTD₄-) and leukotriene C₄- (LTC₄-) induced intracellular calcium mobilization with IC₅₀values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT₁receptor cell line (IC₅₀>10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines^[1].

HAMI 3379 (0.025-0.4 mg/kg; ip) with 0.1-0.4 mg/kg significantly reduces the infarct volume and percentage increase in the ischemic/contralateral hemispheric ratio^[2].
HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holdingangle^[2].

595.72

C₃₄H₄₅NO₈

1245653-57-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.